MYOS RENS TECHNOLOGY INC. MYOS Cash Flow

Myos rens technology inc. (MYOS)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows From Operating Activities:
Net loss
-4,149	-4,258	-3,136	-3,126	-2,985	-3,223	-4,240	-4,082	-4,154	-4,058	-3,728	-3,841	-4,238	-4,341	-4,887	-5,315	-4,769	-5,078	-4,640	-5,523	-5,566	-4,459	-5,008	-3,611	-3,594	-4,263	-3,872	-3,904	-4,505	-3,914	0	0	0	-	-	-	-
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation
50	52	28	28	31	35	39	45	49	51	52	52	53	54	55	56	55	53	51	50	49	49	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization
329	349	442	416	395	395	286	287	286	267	249	230	211	210	210	209	210	210	0	0	0	-	-	-	-	-	20	69	69	69	0	0	0	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Depreciation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	37	26	14	6	1	0	0	0	0	0	0	0
Amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of contract liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-13	-10	-7	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
280	306	133	141	355	235	234	243	242	160	249	248	336	392	464	591	740	930	1,194	1,531	1,675	1,691	1,519	1,341	1,283	1,335	1,132	1,135	1,076	796	835	1,418	1,125	2,550	0	0	0
Provision for inventory reserve
-	-	-	-	-	-	-	-	-	-	-	-	-	107	420	791	733	697	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment charge
-	-	-	-	-	-	-	-	-	-	-	-	-	44	44	44	44	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on debt conversion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-760	-760	0	0	0	-	-	-	-
Impairment charges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-	-	-	0
Interest expense paid in stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-
Derivative charges and credits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-28	-38	190	-2	-16	1,725	-1,981	1,998	1,559	0	0	0
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable
88	10	39	14	18	74	-51	112	-5	55	114	-58	20	-398	-711	-1,055	-1,027	-966	-1,019	-1,271	-423	727	1,516	2,100	1,335	443	-1	230	157	184	0	0	0	-	-	-	0
Decrease (increase) in inventories
-230	-124	-116	-65	-71	-78	-53	-86	-81	-81	-20	497	544	501	459	-11	314	350	415	1,331	1,277	1,999	2,085	1,154	750	-76	-172	-422	-408	-307	-377	772	517	526	0	0	0
Increase in operating lease right of use asset
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Increase) in deferred financing cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	0	0	-	-	-	0
(Increase) decrease in prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-222	348	362	552	600	-45	95	154	61	105	50	-102	-66	-231	399	-12	107	0	0	0
(Increase) decrease in prepaid expenses and other assets
1,096	13	40	85	-1,096	-103	-392	-203	-105	78	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in operating lease liabilities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in accrued interest expense
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in deferred revenue
-	-	-	-	-	-	-	-	-	-56	-46	-36	-56	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in accounts payable and accrued expenses
-182	-103	-208	-136	-93	203	-61	104	-19	-156	-32	-337	-185	-356	-194	-2	233	471	261	-344	-559	78	278	602	691	137	-41	182	-151	-309	-40	42	285	429	0	0	0
Net cash (used in) provided by operating activities
-3,415	-2,367	-2,604	-2,615	-2,157	-3,250	-3,133	-3,030	-3,344	-3,783	-3,842	-4,023	-4,398	-3,673	-3,312	-2,751	-1,978	-2,252	-2,393	-3,965	-4,870	-5,089	-6,072	-4,906	-3,796	-3,154	-2,707	-2,681	-2,379	-2,345	-1,621	-1,458	-2,310	-2,155	0	0	0
Acquisition of intellectual property
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-	-	-	-
Purchases of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23	51	54	118	373	349	339	263	6	2	3	2	3	0	0	0
Acquisition of intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	38	38	37	36	-450	-450	-450	0	0	0	0
Decrease in security deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	0
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-29	-57	-58	-119	-375	-398	-388	-311	-43	7	6	7	-453	0	0	0
Cash Flows From Financing Activities:
Proceeds from registered direct offering of common stock
211	211	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs from at-the-market transaction
-	-	-	-	-	-	-	-	-	102	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Repayments to) advances from related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53	0	27	-140	33	87	0	0	0
Note borrowings
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19	19	0	0	0	-	-	-	-
Repayment of notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	65	415	742	717	742	392	0	0	0
Proceeds from related party promissory note
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-	-	-	0
Proceeds from exercise of warrants, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11	11	0	0	0	-	-	-	-
Repayments of term note
-	-	-	-	-	-	-	-	-	-	-	-	-	100	300	400	400	300	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs from private placement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	0	-	-	-	-	6,869	6,954	1,792	2,078	2,480	0	0	0
Proceeds from issuance of common stock in private placement
1,030	1,850	0	0	0	-	-	-	-	2,944	1,818	1,926	1,926	5,141	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Insurance financing note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-72	-72	-72	0	0	-178	-178	-178	0	0	0	-	-	-	0
Net cash provided by financing activities
1,896	2,416	2,541	3,265	4,124	2,342	3,126	2,396	1,337	2,842	1,802	1,801	1,801	5,041	5,416	5,216	6,632	1,591	2,567	2,987	1,571	6,234	4,883	4,663	4,663	0	-5	5,094	5,685	6,307	6,562	1,495	1,875	2,670	0	0	0
Net increase in cash
-1,519	49	-63	650	1,967	-908	-9	-636	-2,009	-943	-2,421	-2,602	-2,978	987	2,104	2,449	4,627	-688	147	-999	-3,324	1,116	-1,246	-301	747	-3,529	-3,110	2,024	2,994	3,918	4,949	42	-427	61	0	0	0
Interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15	15	15	0	0	0	0	0	0
Income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	4	3	3	2	0	0	0	-	-	-	3	2	2	1	1	0	0	0	0
Supplemental schedule of non-cash investing and financing activities:
Conversion of related party promissory note payable into shares of common stock
825	250	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of deferred offering costs to additional paid in capital
-	-	16	16	16	6	29	29	29	23	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued capital expenditures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Offering costs paid by stockholder
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	25	0	0	0
Conversion of stockholder loan and interest into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	546	546	0	0	0	-	-	-	-
Conversion of stockholder loan into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Conversion of stockholder loan into capital - no shares issued
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	22	0	0	0
Conversion of 9,767 warrants into 1,954 common shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	44	44	0	0	0	-	-	-	-
Note payable - insurance financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	42	0	0	0
Note issued for accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Acquisition of intellectual property through note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-	-	-	0
Financing costs through issuance of restricted common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20	20	0	0	0	-	-	-	0